Purple Biotech Ltd.
PPBT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $58 | $48 | $45 | $40 |
| Gross Profit | -$58 | -$48 | -$45 | -$40 |
| % Margin | – | – | – | – |
| R&D Expenses | $590 | $553 | $760 | $458 |
| G&A Expenses | $0 | $683 | $646 | $0 |
| SG&A Expenses | $725 | $683 | $646 | $310 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $208 |
| Operating Expenses | $1,315 | $1,236 | $1,406 | $976 |
| Operating Income | -$1,373 | -$1,236 | -$1,406 | -$1,016 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $62 | $147 | $950 | $601 |
| Pre-Tax Income | -$1,311 | -$1,089 | -$456 | -$415 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,309 | -$1,085 | -$453 | -$410 |
| % Margin | – | – | – | – |
| EPS | -58 | -80 | -34 | -0.2 |
| % Growth | 27.5% | -135.3% | -16,900% | – |
| EPS Diluted | -58 | -80 | -34 | -0.2 |
| Weighted Avg Shares Out | 23 | 14 | 13 | 2,586 |
| Weighted Avg Shares Out Dil | 23 | 14 | 13 | 2,586 |
| Supplemental Information | – | – | – | – |
| Interest Income | $124 | $73 | $54 | $460 |
| Interest Expense | $5 | $0 | $35 | $0 |
| Depreciation & Amortization | $58 | $47 | $45 | $40 |
| EBITDA | -$1,248 | -$1,042 | -$376 | -$886 |
| % Margin | – | – | – | – |